An observational study in Chronic Pain and Nociplastic Pain, sponsored by University Ghent. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by University Ghent · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Chronic Pain with a site in Belgium — 18 open to participants now, 21 under way, none of them phase 3. Chronic Pain · Belgium.
Among the 79 studies in Chronic Pain with a site in Belgium, this one is the 8th largest by planned enrollment of the 32 observational ones that give a count, is one of 6 that started in 2023, is one of 32 observational ones, reaches primary completion later than 12 of the 20 other live ones, and was the 63rd registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →18 of the 79 studies in Chronic Pain with a site in Belgium are open now. Recruiting first, the newest first:
Medtronic · Sites in Belgium, United States, France and 1 more country
Ages 18+
Université Catholique de Louvain · Sites in Belgium
Ages 18+
Vrije Universiteit Brussel · Sites in Belgium
Ages 18–70 · Healthy volunteers
Vrije Universiteit Brussel · Sites in Belgium
Ages 18–60 · Healthy volunteers
Vrije Universiteit Brussel · Sites in Belgium, Netherlands
Ages 18–65
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 5 · Phase 4 2
First in 2009; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 120 across 755 observational studies indexed under Chronic Pain.
Median enrollment 73 across the 47 interventional studies, 167 across the 32 observational. Of the 49 that completed or were terminated, 14 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 79 have an industry lead sponsor. The 10 most frequent:
University Ghent is the lead sponsor of 350 studies on the registry; 86 are open to participants now.
University Ghent has 4 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
5 of the studies in Chronic Pain with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04531917Universitair Ziekenhuis BrusselThe Effect of Pain Neuroscience Education and Behavioural Graded Activity on Chronic Pain in Breast Cancer Survivors | 2026-12 |
| NCT06892977University GhentMapping Stress and Pain Interactions (G072323N) | 2026-12 |
| NCT06834724Vrije Universiteit BrusselClinical Outcomes of Continuous Positive Airway Pressure Treatment in People With Obstructive Sleep Apnea and Chronic Pain | 2027-04 |
| NCT07453524Université Catholique de LouvainAssessing Chronic Pain Patient Preferences | 2027-07-31 |
| NCT05768477University GhentDifferent Treatments in Chronic Pain Patients. | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 79 studies in Chronic Pain with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to compare different treatment options in a chronic pain population. The main questions it aims to answer are:
Participant data will be gathered as part of their routine care. They can be advised to 4 different treatment options:
Researchers will compare patients with different dominant pain mechanisms to see which treatment are most effective for which dominant pain mechanisms.
The aim of the present study is to describe the natural flow of the chronic pain patients at the pain center AZ Sint-Lucas. Patients will be examined before starting the therapy, and receive standardized questionnaires at several fixed time points (before, during, and after their therapy trajectory). Information about the present dominant pain mechanism will be gathered during the examination. The questionnaires will gather demographic data, information about the present dominant pain mechanism, psychosocial factors, catastrophizing, fear and avoidance, illness perceptions, fatigue and information about therapy success. During the examination, typical signs of a dominant nociplastic pain mechanism will be gathered. By processing the data of the questionnaires and the examination, knowledge about (1) the amount of patients with a dominant nociplastic pain mechanism at intake, (2) the treatment trajectory for a specific diagnosis, and (3) the prediction of the therapy effect and prognosis will be obtained.
The population will be patients attending the pain center of AZ Sint-Lucas in Ghent, a secondary care center for chronic pain patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Chronic pain patients with a dominant nociceptive pain mechanism, a dominant neuropathic pain mechanism and a dominant nociplastic pain mechanism. They will receive different treatments: Consultations, Interventions (injections, denervations...), Baxter therapy and interdisciplinary treatment.
Other: Consultation · Procedure: Interventions · Drug: Baxter therapy · Behavioral: Interdisciplinary therapy
Consultation with the pain specialist, which might entail prescription of medication of vitamins.
Facet injections, nerve denervations, infiltrations, Qutenza, Spinal Cord Stimulation, Transcutaneous Electrical Nerve Stimulation
Ketamine or Linisol baxter therapy
Interdisciplinary therapy provided by the physiotherapist, psychologist and occupational therapist.
Change in Pain disability from baseline until 18 months
Pain Disability Index, ranges from zero to 70, with a higher score indicating more pain-related disability
Time frame: 0 weeks, 4 weeks, 10 weeks, 6 months, 12 months, 18 months
Change in Pain intensity from baseline until 18 months
Numeric Rating Scale for pain intensity in the past week, ranges from zero to 100, with a higher score indicating a higher pain intensity
Time frame: 0 weeks, 4 weeks, 10 weeks, 6 months, 12 months, 18 months
Change in Pain Frequency from baseline until 18 months
Questions
Time frame: 0 weeks, 4 weeks, 10 weeks, 6 months, 12 months, 18 months
Change in Functionality from baseline until 18 months
Patient Specific Complaints questionnaire, using a Numeric Rating Scale, ranging from zero to 100, with a higher score indicating a higher amount of functional disability
Time frame: 0 weeks, 4 weeks, 10 weeks, 6 months, 12 months, 18 months
Change in Quality of Life from baseline until 18 months
EuroQol-5D questionnaire
Time frame: 0 weeks, 4 weeks, 10 weeks, 6 months, 12 months, 18 months
Change in Post exertional malaise from baseline until 18 months
Questions based on the criteria for Chronic Fatigue Syndrome.
Time frame: 0 weeks, 4 weeks, 10 weeks, 6 months, 12 months, 18 months
Change in Quality of Life from baseline until 18 months
EuroQol - 5D, five questions about health range from one to three with a higher score indicating more difficulties. One question about perceived health ranges from zero to 100 with a higher score indicating better health.
Time frame: 0 weeks, 4 weeks, 10 weeks, 6 months, 12 months, 18 months
Plan to share: Yes — The personal data will be shared with the personal electronic patient file of AZ Sint-Lucas, of each patient. Sharing of data will be done upon reasonable request, and only for research purposes, after publication of the results. Data will be shared via a restricted data repository (FAIRsharing.org)
Time frame: The data will not be transferred to a third country. The ethical committee of the pain center of AZ Sint-Lucas did not allow for data transfer upon reasonable request.
Access criteria: The data will not be transferred to a third country.
No publications or documents are linked to this record.
Started Apr 2023 (actual). Primary completion is estimated for Sep 2027, 53 months after the start.
Of 337 non-industry observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 56. This study's planned 53 months is above that.
Counting every sponsor, half of 363 studies reached it within 24 months; a quarter within 12 and three quarters within 56.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Apr 2026 → Sep 2027 and completion Jun 2027 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.